Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 5/20 | 0.41 |
| ▸ | FAAH | O00519 | 4/20 | 0.41 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | PRKCG | P05129 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7000978 | 1.00 | CES2 (0.46) | CES2THRBGMNNTP53POLB | |
| SCHEMBL7001843 | 1.00 | CES2 (0.46) | CES2THRBGMNNTP53POLB | |
| SCHEMBL6721928 | 0.97 | CES2 (0.43) | CES2THRBGMNNTP53POLB | |
| SCHEMBL4159939 | 0.95 | CES2 (0.52) | CES2THRBGMNNTP53POLB | |
| SCHEMBL8811352 | 0.95 | CES2 (0.52) | CES2THRBGMNNTP53POLB | |
| SCHEMBL8050737 | 0.95 | CES2 (0.52) | CES2THRBGMNNTP53POLB | |
| SCHEMBL8813994 | 0.95 | CES2 (0.52) | CES2THRBGMNNTP53POLB | |
| SCHEMBL7001840 | 0.90 | CES2 (0.41) | CES2THRBGMNNTP53POLB | |
| SCHEMBL7002011 | 0.90 | CES2 (0.41) | CES2THRBGMNNTP53POLB | |
| SCHEMBL10590914 | 0.90 | CES2 (0.52) | CES2THRBGMNNTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1655291-B1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. | 2009-12-24 | — | — | US | disclosed |
| US-7601746-B2 | Compounds exhibiting thrombopoietin receptor agonism | SHIONOGI & CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2007-02-22 | — | — | US | disclosed |
| EP-1655291-A1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. (JP) | 2006-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | MPL, TEK, GHRHR | CES2 3634/4885THRB 92/4885GMNN 3766/4885 |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | DHFR, NAT1, ACR | CES2 288/4885THRB 2080/4885GMNN 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.